The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
